Revvity Highlights AUTOCRYPT's Post-Quantum Cybersecurity Solution for the Automotive Industry
- AUTOCRYPT launches "AutoCrypt PKI-Vehicles," a post-quantum cybersecurity solution for automotive systems enhancing security standards.
- The solution utilizes the ML-DSA digital signature algorithm, aligning with NIST standards for post-quantum cryptography.
- AUTOCRYPT showcases its innovations at CES 2026, emphasizing leadership in quantum-safe cybersecurity and regulatory compliance.
AUTOCRYPT Unveils Advanced Post-Quantum Cybersecurity Solution for Automotive Industry
AUTOCRYPT, a leader in automotive cybersecurity, announces the launch of "AutoCrypt PKI-Vehicles," a cutting-edge Public Key Infrastructure (PKI) solution designed to enhance security for automotive systems. This innovative offering features the ML-DSA, a post-quantum digital signature algorithm that positions AUTOCRYPT as one of the pioneers in commercializing quantum-safe cryptographic solutions. The introduction of AutoCrypt PKI-Vehicles aligns with the National Institute of Standards and Technology (NIST) standards for post-quantum cryptography, reflecting a forward-thinking approach in a rapidly evolving industry.
As the automotive sector faces unprecedented challenges from advancements in quantum computing, AUTOCRYPT's initiative focuses on helping manufacturers and suppliers transition to post-quantum solutions while maintaining their existing infrastructures. CEO Seokwoo Lee emphasizes the necessity of this shift, asserting that it is vital for ensuring the cybersecurity of vehicles against emerging threats. By adopting these advanced cryptographic standards, AUTOCRYPT aims to safeguard the future of automotive security and provide peace of mind to stakeholders in the industry.
AUTOCRYPT’s commitment to fostering a secure transportation ecosystem is further highlighted by its participation in the upcoming 2026 Consumer Electronics Show (CES) in Las Vegas, where it will showcase AutoCrypt PKI-Vehicles alongside its award-winning AutoCrypt CSTP product. The CSTP solution aids automotive original equipment manufacturers (OEMs) and suppliers in complying with critical regulatory standards, such as ISO/SAE 21434, WP.29 UN R155, and CRA. This strategic product launch not only reinforces AUTOCRYPT's leadership in quantum-safe cybersecurity but also signals a new era of innovation within the automotive industry.
In addition to its groundbreaking PKI solution, AUTOCRYPT continues to provide integrated security software for in-vehicle systems and related communications. This focus on comprehensive cybersecurity solutions ensures that automotive players can navigate the complexities of modern threats effectively. The company’s participation at CES will offer manufacturers an opportunity to engage directly with AUTOCRYPT’s experts, paving the way for collaborative advancements in automotive cybersecurity.
For further information about AUTOCRYPT and its product offerings, interested parties can visit autocrypt.io.
Related Cashu News

Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…

PTC Therapeutics Raises $500 Million for Debt Management and Growth in Biopharmaceuticals
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…

Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…

Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…